Drug Trial Radar · NCT04856085
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
244
Actual
Start
Jul 11, 2021
Primary completion
Mar 16, 2026
Study completion Mar 16, 2026
Sponsor
- Lead sponsor
- Vir Biotechnology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy
Conditions
- Hepatitis B, Chronic
Interventions
VIR-2218Drug
VIR-2218 given by subcutaneous injection
VIR-3434Drug
VIR-3434 given by subcutaneous injection
PEG-IFNαDrug
PEG-IFNα given by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with treatment-emergent adverse events (TEAEs)Time frame: Up to 72 weeks
- Proportion of participants with serious adverse events (SAEs)Time frame: Up to 72 weeks
- Proportion of participants with hepatitis B surface antigen (HBsAg) loss (defined as undetectable HBsAg) at end of treatmentTime frame: Up to 48 weeks
- Proportion of participants with HBsAg loss (defined as undetectable HBsAg) at 24 weeks post-end of treatmentTime frame: Up to 72 weeks
Locations
37 sites in 12 countries. Site status is shown where the registry gives one.
Investigative Site
San Francisco, California
Investigative Site
Miami, Florida
Investigative Site
Orlando, Florida
Investigative Site
Baltimore, Maryland
Investigative Site
Hillsborough, New Jersey
Investigative Site
Toronto, Canada
Investigative Site
Toronto, Canada
Investigative Site
Vancouver, Canada
Investigative Site
Frankfurt, Germany
Investigative Site
Hanover, Germany
Investigative Site
Mannheim, Germany
Investigative Site
Hong Kong, Hong Kong
Investigative Site
Hong Kong, Shatin, Hong Kong
Investigative Site
Hong Kong, Tai Po District, Hong Kong
Investigative Site
Kuala Lumpur, Malaysia
Investigative Site
Chisinau, Moldova
Investigative Site
Auckland, New Zealand
Investigative Site
Auckland, New Zealand
Investigative Site
Hamilton, New Zealand
Investigative Site
Tauranga, New Zealand
Investigative Site
Wellington, New Zealand
Investigative Site
Bucharest, Romania
Investigative Site
Busan, South Korea
Investigative Site
Seoul, South Korea
Investigative Site
Seoul, South Korea
Investigative Site
Yangsan, South Korea
Investigative Site
Chiayi City, Taiwan
Investigative Site
Kaohsiung City, Taiwan
Investigative Site
Kaohsiung City, Taiwan
Investigative Site
Taichung, Taiwan
Investigative Site
Taipei, Taiwan
Investigative Site
Taoyuan City, Taiwan
Investigative Site
Kyiv, Ukraine
Investigative Site
Birmingham, United Kingdom
Investigative Site
London, United Kingdom
Investigative Site
London, United Kingdom
Investigative Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.